Business Context and Reporting Period
Company: Redhill Biopharma Ltd. (Nasdaq: RDHL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2026 (Date of Filing: July 28, 2026)
Primary Focus: Update on the development of opaganib (ABC294640) as a potential treatment for the Bundibugyo ebolavirus (BDBV) outbreak.
Key Financial Metrics
This filing is a current report regarding a press release and does not contain audited financial statements, revenue figures, profit data, cash flow statements, or specific liquidity metrics. The filing text does not provide a clear value for financial performance.
Material Changes and Operational Updates
- Ebola Outbreak Status: Confirmed Bundibugyo ebolavirus (BDBV) cases have risen to 3,221 with 1,407 deaths as of July 28, 2026.
- Partnership Discussions: Redhill is finalizing development next steps and engaging in potential partnership discussions with the African Medicines Agency (Emergency Task Force), the Ugandan Ministry of Health, Mbarara University of Science and Technology (MUST), and the Democratic Republic of Congo (DRC) Scientific Advisory Committee.
- Commercial Acquisition: Cumberland Pharmaceuticals, Redhill's U.S. co-commercialization partner for Talicia, was acquired by Apotex Health Corp. on July 1, 2026.
Guidance, Outlook, and Management Commentary
Opaganib Development Rationale
Management highlights opaganib as a host-directed antiviral with an oral formulation and established safety profile. Key data points cited include:
- Clinical Data (COVID-19 Analogue): In a Phase 3 study for severe COVID-19, opaganib added to standard of care (remdesivir + corticosteroids) reduced mortality by 70.2% (6.98% vs. 23.4%) and improved median time to viral RNA clearance by at least 4 days.
- Preclinical Data (EVD): USAMRIID-funded studies showed opaganib inhibited EVD in human macrophages, increased survival in one of two animal models, and demonstrated a synergistic effect when combined with remdesivir.
- Mechanism of Action: Opaganib is an SPHK2 inhibitor that may disrupt host-cell components essential for filovirus entry and replication, inhibit the PI3K/Akt pathway, and suppress immune dysregulation (NLRP3 inflammasome, IL-6/TNFα).
Risks and Contingencies
The filing includes extensive forward-looking statement disclaimers. Key risks identified include:
- Opaganib may not be accepted into Ebola virus disease control programs or may fail to demonstrate efficacy in the current outbreak.
- Uncertainty regarding continued U.S. government research and development funding (BARDA).
- Risks related to Nasdaq listing compliance, specifically the minimum bid price requirement.
- Potential failure of other development programs, including RHB-204 for Crohn's disease and RHB-102 for GLP-1/GIP-related GI intolerance.
Investor Verification Checklist
- Verify the status of partnership agreements with the African Medicines Agency and Ugandan/DRC health authorities regarding opaganib deployment.
- Confirm the impact of the Cumberland Pharmaceuticals acquisition by Apotex Health Corp. on Redhill's Talicia revenue stream.
- Review the Company's most recent Form 20-F (filed April 27, 2026) for actual financial position, cash runway, and debt levels not included in this 6-K.
- Monitor Nasdaq compliance status regarding the minimum bid price requirement.
- Assess the timeline for potential Emergency Use Authorization (EUA) or stockpiling of opaganib for the Ebola outbreak.